In RCC specifically, ex vivo studies using tumour fragments from RCC patients have demonstrated that GPR65 inhibition modulates cytokine profiles within the TME, suggesting that the acid-sensing GPR65 pathway may contribute to the immunosuppressive landscape characteristic of this malignancy [65,67,123]. The gene discussed is GPR65; the disease is neoplasm.